|
Venus MedTech (HangZhou) Inc. is a China-based company engaged in the research, development, manufacture and sales of minimally invasive medical devices and auxiliary instruments and equipment for the treatment of heart valve diseases. The Company's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8 / TAV8 and TriGUARD3 Cerebral Embolic Protection Device.
Number of employees : 905 people.
|
|
| 2020 | 2021 | Delta | VenusA-Valve/VenusA-Plus | 305.66 | 98.5% | 488.53 | 97.5% | +59.83% |
TriGUARD3 | 3.76 | 1.2% | 11.31 | 2.3% | +200.61% |
Others | 0.78 | 0.2% | 1.37 | 0.3% | +76.43% |
HKD in Million |
|
|
| 2020 | 2021 | Delta | China | 305.66 | 98.5% | 488.53 | 97.5% | +59.83% |
Others | 4.54 | 1.5% | 12.67 | 2.5% | +179.39% |
HKD in Million |
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
Stock A |
1 |
441,010,235 |
351,370,129 |
79.7% |
0 |
0.0% |
79.7% |
Stock B |
0 |
1,208 |
0 |
0.0% |
0 |
0.0% |
|
|
Name | Equities | % | Qiming Venture Partners Ltd. | 58,777,980 |
13.3% | Min Zeng | 33,651,618 |
7.63% | Zhen Jun Zi | 32,197,802 |
7.30% | GIC Pte Ltd. (Investment Management) | 22,041,119 |
5.00% | Fidelity Management & Research Co. LLC | 18,670,032 |
4.23% | JPMorgan Asset Management (Asia Pacific) Ltd. | 13,888,500 |
3.15% | Dcp Ltd. | 12,394,252 |
2.81% | Jiaxing Demenghong Investment Partnership LP | 10,628,724 |
2.41% | Zhong Ou Asset Management Co., Ltd | 8,987,500 |
2.04% | The Vanguard Group, Inc. | 8,225,634 |
1.87% |
|
Company contact information |
|
Venus Medtech (Hangzhou), Inc. 40th Floor Dah Sing Financial Centre No. 248 Queen's Road East Wanchai, Zhejiang 310053 Phone : +86.571.87772183 Web : http://www.venusmedtech.com
|
|
|
Sector Medical Devices & Implants
Connections : Venus Medtech (Hangzhou) Inc.
|